Trial Profile
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Evaluation of Twice Daily PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis in Subjects 3 Months to Less Than 18 Years of Age
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2014
Price :
$35
*
At a glance
- Drugs PDI 192 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors PreCision Dermatology
- 03 Apr 2014 New trial record